The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Remnant lipoproteins as therapeutic targets
Abstract
Increasing evidence suggests that subsets of triglyceride-rich lipoproteins are particularly atherogenic. These include particles with some, but not necessarily all the properties classically attributed to remnants. Cholesteryl ester-enrichment seems to be a common feature of these particles, some of which can be taken up by macrophages by a novel receptor that recognizes species of apolipoprotein B but not apolipoprotein E. These characteristics seem to be common to postprandial and hypertriglyceridemic very low density lipoproteins as well as chylomicron remnants. Remnant-like triglyceride-rich lipoproteins that exhibit several potentially atherogenic properties can be quantified by a simple test that shows promise for identifying individuals at high risk for lesion formation and clinical events. Available hygienic and pharmaceutical measures that effectively lower the concentration of atherogenic triglyceride-rich lipoproteins deserve wider use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zilversmit et al. proposed that the increase in the postprandial levels of remnant lipoprotein after meals can cause atherosclerosis. Considerable evidence has been accumulated thereafter, and this hypothesis has therefore been established as the disease concept238, 243–245).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [244]
Citations
Cites
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Plasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease
Kohler, H. P., & Grant, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422406 · Cited by 805
Nakajima, K., SAITO, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., Campos, E. M., et al. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90062-9 · Cited by 417
Self-citationApoprotein composition of very low density lipoproteins of human serum.
Kane, J. P., Sata, T., Hamilton, R. L., & Havel, R. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108245 · Cited by 376
Self-citationPostprandial lipoprotein metabolism and atherosclerosis.
Karpe, F. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00548.x · Cited by 360
Sata, T., Havel, R. J., & Jones, A. L. (1972) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39346-9 · Cited by 359
Self-citationFreedman, D. S., Otvos, J. D., Jeyarajah, E. J., Barboriak, J. J., Anderson, A. J., & Walker, J. A. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.7.1046 · Cited by 345
Mjøs, O. D., Færgeman, O., Hamilton, R. L., & Havel, R. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108130 · Cited by 322
Self-citationKugiyama, K., Doi, H., Takazoe, K., Kawano, H., Soejima, H., Mizuno, Y., Tsunoda, R., Sakamoto, T., Nakano, T., Nakajima, K., et al. (1999) · Circulation · doi:10.1161/01.cir.99.22.2858 · Cited by 284
Research works printed but not linked: 4
- Nakajima, 1997, J Clin Ligand Assay, 19, 177
- Wang, 1999, Clin Chem, 45, 1981
- Sekihara, 1996, Jp J Nephrol, 38, 220
- Abbasi, 1999, J Clin Endocrinol Metab, 84, 3903
Cited by
Sorted by citations
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Metadata
- Authors
- Havel, R. J.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Havel, Richard J.
- Venue
- Current Opinion in Lipidology
- Published
- 2000-12
- Volume
- 11
- Issue
- 6
- Pages
- 615-620
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2084853272
- Cited by
- 107
- References
- 59
- Citations by year
- 2026: 2 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 6 · 2018: 6 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 7 · 2012: 3
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- remnant lipoproteins, triglyceride-rich lipoproteins, atherogenic lipoproteins, macrophage uptake, chylomicron remnants, VLDL, postprandial lipemia, hypertriglyceridemia, atherosclerosis risk assessment, therapeutic target, lipid-lowering therapy
- MeSH terms
- Animals, Apolipoproteins B, Apolipoproteins E, Arteriosclerosis, Cholesterol Esters, Chylomicrons, Humans, Lipoproteins, Lipoproteins, HDL, Lipoproteins, VLDL, Macrophages, Triglycerides, Hypertriglyceridemia, Chylomicron Remnants
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
